13 Biotechnology Stocks to Buy Now

13 Biotechnology Stocks to Buy Now

This week, 13 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

CoLucid Pharmaceuticals, Inc. (CLCD) boosts its rating from a B to a A this week. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CLCD stock.

This week, Clovis Oncology, Inc. (CLVS) pushes up from a D to a B rating. Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of CLVS stock.

Albireo Pharma, Inc. (ALBO) is seeing ratings go up from a B last week to a A this week. For more information, get Portfolio Grader’s complete analysis of ALBO stock.

Vanda Pharmaceuticals Inc. (VNDA) gets a higher grade this week, advancing from a B last week to a A. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VNDA stock.

XBiotech, Inc. (XBIT) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of XBIT stock.

ARIAD Pharmaceuticals, Inc. (ARIA) shows solid improvement this week. The company’s rating rises from a B to a A. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

Natera, Inc. (NTRA) improves from a C to a B rating this week. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of NTRA stock.

This week, Chemocentryx, Inc.’s (CCXI) ratings are up from a C last week to a B. Chemocentryx, Inc. a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CCXI stock.

Array BioPharma Inc.’s (ARRY) ratings are looking better this week, moving up to a B from last week’s C. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

This is a strong week for Abeona Therapeutics, Inc. (ABEO). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ABEO stock.

The rating of Kindred Biosciences, Inc. (KIN) moves up this week, rising from a C to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of KIN stock.

Aurinia Pharmaceuticals Inc. (AUPH) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

This week, CASI Pharmaceuticals Inc’s (CASI) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of CASI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/13-biotechnology-stocks-to-buy-now-3/.

©2019 InvestorPlace Media, LLC